Containment by Design for Cytotoxic Manufacturing
Innovative containment solutions aim to minimize workers' exposure to cytotoxic compounds and ensure these compounds are not contaminated.
Bridging the Development–Manufacturing Gap to Achieve QbD and PAT
To implement QbD and reduce business risks, teams should begin QbD collaboration early during process development.
February 2009 Editor's Picks: Products from Oystar USA and Schreiner MediPharm
PharmTech's monthly newsletter, Equipment & Processing Report, reviews the Editor's Picks for the February 2009 edition from Oystar USA and Schreiner MediPharm.
